Canada· CA-DIN-02387166
NEOSTIGMINE OMEGA
A neostigmine product containing neostigmine methylsulfate, registered in Canada by OMEGA LABORATORIES LIMITED. The same ATC class is registered in 10 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Neostigmine is registered in 10 of 19 countries.
Countries holding a registration under ATC N07AA01 (neostigmine), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 6 of them publish a price we can compare per daily dose
Neostigmine · ATC N07AA01
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- NEOSTIGMINE METHYLSULFATE
- Manufacturer
- OMEGA LABORATORIES LIMITED
- Country
- Canada (CA)
- ATC code
- N07AA01
- ATC class
- Neostigmine
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
68 interactions on record for neostigmine.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Neostigmine · interactions on record
68 records
- 6 severe
- 62 moderate
Most severe, free to view
- SiponimodL04AA42severe
- SiponimodL04AE03severe
- BupropionN06AX12severe
- BupropionN07BA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Neostigmine in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBloxiverzExela Pharma Sciences, LLC
- GermanyNeostigCarinopharm Gmbh
- BelgiumProstigmine 0.5 mg/mlViatris Healthcare
- NetherlandsNeostigminemethylsulfaat CF 0,5 mg/ml, injectievloeistofCentrafarm B.V.
- FranceNEOSTIGMINE RENAUDIN 5 mg/5 mL, solution injectableLABORATOIRE RENAUDIN
- NorwayNeostig-carinopharmCarinopharm
- PolandPolstigminumTeva Pharmaceuticals Polska Sp. z o.o.
- CzechiaSYNTOSTIGMINBB Pharma a.s., Praha
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Austria · Neostig, Normastigmin
- Cyprus · Neostigmine Cooper
- Czechia · Syntostigmin
- Germany · Neostig, Neostigmin Panpharma
- Spain · Neostigmina Braun
- France · Néostigmine Renaudin, Prostigmine
- United Kingdom (Northern Ireland) · Neostigmine Methylsulfate Bp Hameln Pharma
- Greece · Neostigmine Cooper
- Croatia · Neostigmin Panpharma
- Hungary · Neostigmine Kalceks, Stigmosan
- Latvia · Neostigmine Kalceks
- Netherlands · Neostigminemethylsulfaat Cf, Prostigmin
- Poland · Polstigminum
- Portugal · Neostigmina Braun
- Romania · Miostin
- Sweden · Neostigmin Unimedic Pharma Ab
- Slovakia · Syntostigmin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/34159d04-4157-4e49-a8ae-7a3007b7ab63 GET /v1/drugs/34159d04-4157-4e49-a8ae-7a3007b7ab63?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02387166",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS",
"INTRAVENOUS",
"INTRAMUSCULAR"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "N07AA01",
"schedule": [
"Prescription"
],
"drug_code": "87274",
"strengths": [
"2.5 MG"
],
"ahfs_class": null,
"substances": [
"NEOSTIGMINE METHYLSULFATE"
],
"product_categorization": null
}See everything about neostigmine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.